

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2018/225065 A9

(43) International Publication Date
13 December 2018 (13.12.2018)

WIPO | PCT

(51) International Patent Classification:

C07H 15/224 (2006.01) A61P 21/04 (2006.01)
C07H 15/23 (2006.01) A61P 21/00 (2006.01)
C07H 15/222 (2006.01)

(21) International Application Number:

PCT/IL2018/050612

(22) International Filing Date:

05 June 2018 (05.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/515,021 05 June 2017 (05.06.2017) US

(71) Applicant: **ELOXX PHARMACEUTICALS LTD.**
[IL/IL]; 10 Prof. Menachem Plaut Street, 7670621 Rehovot
(IL).

(72) Inventors: **BAASOV, Timor**; 22 Gilboa Street, 3271630
Haifa (IL). **FIRZON, Vera**; 11B Avraham Liessin Street,
3522219 Haifa (IL). **BELAKHOV, Valery**; 5/2 Yaakov
Hazan Street, 3288105 Haifa (IL). **EYLON, Bat-Hen**; 13
Avraham Stern (Yair) Street, 4440727 Kfar-Saba (IL).

(74) Agent: **EHRlich, Gal et al.**; G. E. Ehrlich (1995) LTD.,
11 Menachem Begin Road, 5268104 Ramat Gan (IL).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS



(57) Abstract: Novel aminoglycosides, represented by Formulae (e.g., a compound of Formula A, B, I, I*, III or III*, including compounds represented by Formula Ia, I**, I*a, I*b, IIIa, III**, III*a and, III*b), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:

16 May 2019 (16.05.2019)

(15) Information about Correction:

see Notice of 16 May 2019 (16.05.2019)